Patients With Treatment-Naïve CLL Treated With BTK Inhibition

Subgroup and Toxicity Analyses Favor Zanubrutinib Vs Ibrutinib in CLL

During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed subgroup analyses and adverse events from the ALPINE trial of zanubrutinib for a patient with relapsed/refractory chronic lymphocytic leukemia in the second article of a 2-part series.

Leslie Reviews Relevant Data for Treatment of Relapsed/Refractory CLL

During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed Bruton tyrosine kinase inhibition options for a patient with relapsed/refractory chronic lymphocytic leukemia in the first article of a 2-part series.

Considering the Durability of Zanubrutinib in Relapsed/Refractory CLL

During a Case-Based Roundtable® event, Marc S. Hoffmann, MD, discussed his viewpoints on the use of Bruton tyrosine kinase inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia and the efficacy behind zanubrutinib in the second article of a 2-part series.

Hoffmann Discusses Deciding Factors for Treating Patients With CLL

In the first article of a 2-part series, Marc S. Hoffmann, MD, looks at the factors to take into consideration before initiating another line of treatment in patients with chronic lymphocytic leukemia.

Managing Cardiac Toxicities with Zanubrutinib in Relapsed CLL

In the second article of a 2-part series, Sameer A. Parikh, MBBS, looks at the risk of cardiac related toxicities with zanubrutinib for patients with relapsed chronic lymphocytic leukemia.

ALPINE Trial Data Shows Effectiveness of Zanubrutinib in Relapsed CLL

In the first article of a 2-part series, Sameer A. Parikh, MBBS, discusses the makeup and design of the phase 3 ALPINE study that showed the promise for the next-generation Bruton tyrosine kinase inhibitor zanubrutinib.

Second Generation BTK Inhibitors Improve Survival in R/R CLL Setting

In the second article of a 2-part series, William G. Wierda, MD, PhD, looks at the efficacy and safety outcomes with the second generation BTK inhibitor zanubrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.

Fitting Second Generation BTK Inhibitors into the R/R CLL Setting

In the first article of a 2-part series, William G. Wierda, MD, PhD, discusses the role Bruton tyrosine kinase inhibitors play in the relapsed/refractory chronic lymphocytic leukemia setting.